The second webinar in the Precision Oncology Showcase series, sponsored by SOPHiA GENETICS, will highlight the successful decentralization of MSK-ACCESS® on the SOPHiA DDM™ Platform. We will explore findings from our internal verification study, insights from early adopter sites, and real-world data that demonstrate how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) has overcome decentralization challenges—delivering high analytical concordance with single-site testing.

We are also excited to welcome Leah Thompson, MB (ASCP)CM, Lab Technician at Tennessee Oncology, who will share her experience verifying and implementing MSK-ACCESS® powered by SOPHiA DDM™. She will discuss analytical performance, workflow simplicity, and the ease of integrating the solution into a laboratory setting.

Key Discussion Points:

• Decentralizing MSK-ACCESS® – Challenges and solutions for ensuring analytical accuracy, managing site variability, and optimizing workflows.
• Performance & Validation – How the SOPHiA DDM™ Platform maintains high concordance through advanced analytics, noise reduction, and standardized wet-lab processes.
• Real-World Adoption – Leah Thompson, MB (ASCP)CM shares insights on assay verification, workflow efficiency, and the ease of use in routine lab operations.

Learning Objectives:

• Understand the Challenges of Decentralization – Learn about the complexities involved in decentralizing MSK-ACCESS® and how the SOPHiA DDM™ Platform addresses key hurdles such as analytical accuracy, wet-lab standardization, and noise reduction.
• Evaluate Performance and Real-World Verification – Gain insights into the internal verification study results and real-world data from seven early adopter sites, demonstrating high analytical concordance between the decentralized and single-site versions of MSK-ACCESS®
• Explore Ease of Adoption and Workflow Efficiency – Understand how MSK-ACCESS® powered with SOPHiA DDM™ offers a streamlined workflow, reliable data quality, and a straightforward implementation process for laboratories.

June 10, 2026 | 1:00PM SGT

Liquid biopsy (LBx) has emerged as a non-invasive genomic profiling approach to guide decision-making and to monitor resistance in cancer, especially when access to tumor tissue is limited. However, one of the key challenges of LBx is distinguishing somatic variants from clonal hematopoiesis (CH)-derived variants, which can occur in biologically relevant genes and confound variant interpretation. In this webinar, Dr. Keller and Dr. Fares (IUCT Oncopole, France) will explore real-world cases where insights from MSK-ACCESS® powered with SOPHiA DDM™ helped inform decisions. The decentralized liquid biopsy solution integrates matched white blood cell (WBC) DNA sequencing to filter out CH and germline variants, increasing confidence in the somatic origin of detected alterations.

By attending this session, you will gain:

• Practical insights into the clinical utility of liquid biopsy
• An understanding of how CH confounds variant interpretation
• Real-world examples of how matched tumor-normal analysis helps inform decision-making

May 6, 2026 | 1:00PM SGT

MSK-IMPACT is a targeted tissue-based sequencing test for comprehensive genomic profiling. MSK-ACCESS is a liquid biopsy test that enables non-invasive profiling and longitudinal disease monitoring. Together, they provide robust insights that help guide treatment decisions for improved outcomes in patients with advanced cancer. Unlike most tests, MSK leverages matched tumor-normal sequencing to remove germline and clonal hematopoietic variants, revealing genomic alterations of true somatic origin.

In this webinar, A. Rose Brannon, director of clinical bioinformatics at MSK, and Anita S. Bowman, associate director of clinical bioinformatics at MSK, will:

• Highlight the benefits of matched tumor-normal sequencing to reduce biological false positives.
• Discuss the clinical utility of combining tissue- and cell-free DNA-based sequencing approaches, with insights from real clinical cases.
• Explore opportunities for clinical, translational, and basic research.

May 27, 2026 | 1:00PM SGT

• Florian Klemm, MD, PhD – Technical Product Manager, SOPHiA GENETICS​
• Ryan Demers, MSc – Global Diagnostics Director, Lung and Liquid Biopsy Strategy, AstraZeneca​
• Persephone du Parcq, MSc, PGDip, - Deputy Operations Lead, Synnovis

MSK-ACCESS® powered with SOPHiA DDM™ offers an innovative and decentralized solution that combines MSK’s expertise in cancer genomics with the robust analytics of the SOPHiA DDM™ Platform. This application aims to address the global inequalities in comprehensive cancer care.​

Watch to hear about the collaborative efforts of SOPHiA GENETICS and AstraZeneca in expanding global access to and adoption of MSK-ACCESS® powered with SOPHiA DDM™. In this session, you will​

• Learn about the decentralized approach, technology, and the analytical performance of this liquid biopsy application.​
• Explore the journey of creating a global network for liquid biopsy testing, including efforts to reach underserved regions where access is limited.​
• Gain insights from the first hands-on experience with MSK-ACCESS® powered with SOPHiA DDM™ from one of the early-access healthcare institutions.​

June 17, 2026 | 1:00 PM SGT

Liquid biopsy has emerged as a revolutionary technology in the precision medicine field, by offering a non-invasive alternative to traditional tumor biopsies. While its potential for tumor detection and monitoring continues to grow, global adoption remains limited due to technical, workflow, and access-related barriers.​ In a leading partnership with AstraZeneca, SOPHiA GENETICS is expanding access to liquid biopsy testing through the deployment of MSK-ACCESS® powered with SOPHiA DDM™, a best-in-class and decentralized NGS-based assay. ​

Join this insightful workshop to explore how a decentralized approach enables broader patient access to testing and accelerates pharmaceutical development, setting new standards in precision oncology.

In this session you will:​

• Discover how the SOPHiA GENETICS decentralised approach and advanced analytics enables scalable, robust, and reproducible liquid biopsy testing, through its decentralized approach, supported by large-scale evidence generation studies across local deployments.​
• Gain insights into the clinical impact and utility of adopting MSK-ACCESS® powered with SOPHiA DDM™, and how it improves access and outcomes for cancer patients.​
• Explore how decentralized testing strategies support late-stage pharmaceutical development and drive commercial success in precision medicine.​

SOPHiA GENETICS and Myriad Genetics have joined forces in a unique partnership combining Myriad’s centralized CDx and regulatory expertise with SOPHiA GENETICS’ decentralized, data-driven platform.

In this engager we explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access to precision medicine. Attendees will:

• Discover SOPHiA GENETICS’ and Myriad Genetics’ first-of-its kind CDx partnership model to unlock scale, regulatory compliance, and access to precision diagnostics and therapies.
• Gain insights into what a co-development strategy for CTA and CDx looks like in practice and how it enables simultaneous development and deployment at a central lab.
• Understand how Pharma-Diagnostics collaborations can support late-stage clinical development through commercialization.

Topics:

• The Hybrid CDx Model: A New Paradigm for Pharma Partnerships
• The Business Structure Behind SOPHiA GENETICS and Myriad Genetics Alliance
• Co-Developing a CTA-CDx: What Does it Look Like in Practice?
• From Single-Site CDx to a Global Distributed Kit: Scaling with the SOPHiA GENETICS Vision
• Going Beyond a Single Test: Expanding Myriad Genetics’ Portfolio
• Panel Discussion: Is a Hybrid Model the Future?

Speakers:

• Kristina McGuire – Executive Director & Head, Precision Medicine Laboratory Operations & Companion Diagnostics, Regeneron
• Lou Welebob – Senior Vice President of BioPharma Companion Diagnostics, Myriad Genetics
• Jess Lambe - Vice President & Managing Director, BioPharma Business Development, SOPHiA
• Vern Geckler – Senior Director, Alliance Management, Myriad Genetics
• Julien Pontis - Head of CDx & Clinical Diagnostics, SOPHiA GENETICS
• Drew Gibbs – Vice President, Business Development, Myriad Genetics
• Yves Serroen - Director, BioPharma Business Development, SOPHiA GENETICS
• Janni Mirosevich – Senior Director, BioPharma Business Development, SOPHiA GENETICS
• Dale Muzzey – Chief Scientific Officer, Myriad Genetics
• Jonathan Beer – Senior Director, Precision Medicine, Bristol Myers Squibb
• Brian Baker – Executive Director, Regulatory Affairs, In Vitro Diagnostics, Regeneron
• Michael Senior – Senior Director, Diagnostic Partnerships, Oncology Business Unit, AstraZeneca

SOPHiA GENETICS will be at the Association for Molecular Pathology Europe Congress (AMP Europe) 2026 in Tallinn, Estonia. Find us at Booth #13 where our team of experts will be ready to discuss how SOPHiA DDM™ platform is helping laboratories and healthcare institutions advance data-driven oncology insights. 

Come explore our partnership with the Memorial Sloan Kettering Cancer Center and our latest updates across the MSK solutions portfolio, including enhanced CNV detection with tumor purity and ploidy analysis in MSK-IMPACT® Flex, and new capabilities in MSK-ACCESS® including MSI and ctDNA fraction, now available on GEN2. 

Also learn more about OncoKB™ which is now fully embedded in SOPHiA DDM™ oncology workflows, and what that means for somatic variant interpretation in practice. 

Industry Symposium

Join our Industry Symposium to explore how combining MSK-IMPACT® Flex and MSK-ACCESS® on the SOPHiA DDM™ Platform unlocks deeper, more complete oncology insights. From real-world use cases to the latest liquid biopsy enhancements, this is a must-attend session for those looking to take their genomic profiling further. 

Monday, 15 June  | 2:30pm – 3:30pm | Ballroom 

Integrating tissue and liquid biopsy for in-depth precision oncology insights 

Dr. Maria De Bonis, Biologist and Health Manager, Fondazione Policlinico A. Gemelli IRCCS, Italy 
Lina Li, Product Director of Solid Tumors, SOPHiA GENETICS 

ASCO 2026 Edition

The SOPHiA GENETICS™ Global Precision Medicine Forum returns to Chicago! Join us on May 29^th at 3:00 PM CST at The Metropolitan in Chicago, IL, for its 2026 edition.

Two years ago, SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) started a liquid biopsy revolution that has since grown into a global shift in precision oncology access. This forum brings together the minds behind that shift to reflect on what was built, its real-world impact, and reveal what comes next.

Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From MSK to the World, and how it is reshaping the future of cancer care.

Across different sessions, the forum will explore:

• From One Lab to the World: Liquid Biopsy as a Leapfrog Technology
• The Power of the Network in Expanding Access to Advanced NGS Liquid Biopsy
• Strategic Partnerships: The Engine Drivers
• Leading Advances in Precision Oncology with Open Innovation

Don't miss this unique opportunity and reserve your spot now!

Speaker: Persephone du Parcq, Lead Clinical/Translational Scientist, Synnovis, UK

In this webinar, Dr. Persephone du Parcq shares how Synnovis has deployed the MSK-ACCESS™ powered with SOPHiA DDM™ to support precision oncology through minimally invasive liquid biopsy testing.

The webinar explores current clinical applications of ctDNA analysis, its demonstrated utility in routine healthcare, and key considerations around assay selection, validation strategies, and interpretation challenges including germline findings and clonal haematopoiesis. Practical insights into clinical impact, operational achievements to date, and lessons learned from clinical implementation are also discussed.

Finally, the session looks ahead to future directions for liquid biopsy in oncology, including opportunities to expand clinical adoption and improve patient care through advanced genomic technologies.

We are thrilled to be at the inaugural World Clinical Biomarkers & Companion Diagnostics Summit Japan. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.

The SOPHiA GENETICS team is thrilled to see you join our Plenary Talk.

Plenary talk on Tuesday, May 19^th from 12.50 to 1.20 pm.

“Liquid Biopsy in Japan: From Global Vision to Local Reality”

Philippe Menu, MD, PhD, MBA, EVP, Chief Medical & Product Officer, SOPHiA GENETICS

Michel Mommejat, President/Representative Director and Chief Innovation Officer, A.D.A.M. Innovations

• Learn how local partnerships are essential to scaling precision oncology globally, streamlining regulatory pathways, and broadening patient access across diverse healthcare settings.
• Delve into the vision that brought SOPHiA GENETICS and MSK together to bring a best-in-class liquid biopsy assay from one lab to the world, to guarantee equal care across borders.
• Understand the evolving landscape of NGS-based liquid biopsy adoption and the remaining barriers to equitable access globally.
• Discover how the strategic partnership between SOPHiA GENETICS and A.D.A.M. Innovations is navigating Japan’s regulatory and infrastructural complexities to unlock the full potential of liquid biopsy for patients across the country.